Tags Posts tagged with "wolf of weed street"

wolf of weed street

0 1876

Palmer Republican Shelley Hughes introduced a proposal recently (Senate Bill 6) that would Permit for the creation of an Alaska hemp industry fully separate from commercial cannabis. Hughes said she introduced the proposal after hearing from farmers in the Matanuska-Susitna Borough who would like to cultivate hemp, particularly to feed livestock. Hughes said, “I’m hoping it maybe, in a small way, opens up an economic opportunity for Alaskans.” She noted the vast array of goods that can be created from hemp (some estimate more than 25,000 possible products) including food and construction materials.

It is still unknown if the crop will be profitable in Alaska. Hughes pointed to a 1916 document from the Alaska Agricultural Experiment Stations that says hemp “fruited abundantly” during a summer crop in the then-territory. Former Senator Johnny Ellis introduced a similar proposal last session that did not make it through the Legislature. Hughes had to reintroduce it, and adjusted it after reviewing hemp federal guidelines. Under the proposal, hemp would be considered an agricultural product, and excluded from Alaska’s definition of cannabis. The hemp industry would be managed by the Division of Agriculture, instead of the Alcohol and Marijuana Control Office.

Strictly controlled, state-run hemp pilot programs were made legal at the federal level by the 2014 Federal Farm Bill. Under Senate Bill 6, Alaska’s farmers would be able to produce, process, and sell hemp. An individual, college, or the Alaska Department of Natural Resources could partake in the pilot program. Hemp would be defined in Alaska statutes as cannabis sativa L., containing no more than 0.3 percent THC. That’s the common definition both at a federal and state level, which the California-based Project CBD says originated from a 1976 taxonomic report by a Canadian plant scientist who never intended to create the legal standard for cannabis vs hemp.

4 10815

By Jason Spatafora @WolfofWeedSt

“I fear the Greeks, even those bearing gifts.”- Virgil

The DEA’s recent cannabis research expansion is a Harry Houdini inspired smoke show of misdirection all to set up the next trick; there I said it. While some view it as a positive first step, I tend to think it served a very deliberate function. Optically it played directly into expected vitriolic fallout from advocates, activists and media touts, all of which lined up to ignite their “DEA should reschedule cannabis” torches. In a “perfect world” scenario these people aren’t wrong, cannabis isn’t Heroin’s equal & 1+1=2, but just as fire cannot exist in a vacuum, neither can a rational cannabis debate. And while everyone on the side of reason is shouting in unison about rescheduling they failed to see that they might have just had their pockets picked. DEA’s policy statement that everyone seemed to ignore there are 33 words that have the potential to create the legal framework for the monopolization of Cannabis by means of an exclusionary application process.

Prologue – August 10th, 2016

Russ Baer, a staff coordinator for the Drug Enforcement Administration (DEA) media affairs wing gave a response to Steven Nelson of USNEWS.com via email. Nelson later shared a screen grab of the email via tweet. The statement made to him from this Drug Enforcement Administration staff coordinator read:

“Tomorrow morning (August 11th, 2016) the Drug Enforcement Administration will be making some important announcement regarding Marijuana related topics that will be published in the Federal Register. Because of your interest and/or prior engagement with the DEA on this subject, the DEA office of National Media Affairs is reaching out to you regarding these anticipated announcements.”

Over the next 24 hours social media was a blaze, with many people within the industry uncovering the fact that Rescheduling wouldn’t happen and that the DEA response would have to do with research. As expected, the incendiary scheduling of cannabis debate raged on into the following day.

August 11th, 2016

As expected, the Drug Enforcement Administration disappointed the advocates and activists of medical marijuana by not removing or rescheduling marijuana from its class 1 controlled substance status. Yet the DEA, in all of its benevolence, offered a consolation prize of sorts, by “deciding” to expand the study of Medical Marijuana for researchers, Universities & drug companies outside of the confines of a single federally legal facility. The facility, to refresh your memory is located at the University of Mississippi, (ranked 164th in Bio Sciences) and had up to this point been the sole research monopoly on legally grown marijuana, courtesy of the NIDA (National Institute on Drug Abuse).

DEA’s Misdirection Strategy

Over the next few days it seemed that every headline following the DEA’s deliberation was about the archaic rescheduling system & how cannabis is safer statistically than opiates that are schedule 2. Some media outlets went as far as to paint a “glass half full” picture. The LA Times for example did a piece titled “DEA ends its monopoly on marijuana growing for medical research.” The social reaction from cannabis enthusiasts, advocates and potrepreneurs from Main Street to Wall Street was as expected with everyone chiming in on social media to wag their fingers at the DEA. Representative Barbara Lee, a congresswoman from Oakland California stating via tweet “Politicians aren’t doctors or scientists. Marijuana research prohibitions are outdated, unscientific, & dangerous for those who need #MMJ.” As expected the rhetoric from the cannabis side was “The DEA is bad, the War on Drugs is a complete failure, Big Pharma is to blame,” so on and so forth.


The people aren’t wrong on many of these points. The War in Drugs is a failure when considering addiction has been plateauing since its 1970 inception and US drug control spending is up 2000%, which to date stands at $1.5 trillion dollars. We can go on and on as to where that money went, what industries it created (prison industrial complex), the people it disproportionately targeted (minorities), but that’s a whole other article or book for that matter. Big Pharma however does have its trillion dollars hands in this story, but more on that later as I’ve digressed.

Not to go back and pick on the LA Times click-bate headline of “DEA ends its monopoly on marijuana growing for medical research,” but did it really end the monopoly? Let’s evaluate the idea. Yes, a monopoly is defined as “the exclusive possession or control of the supply or trade in a commodity or service.” The University of Mississippi was in fact in exclusive possession of the NIDA edict to legally grow marijuana and study it. On the surface the Monopoly has ended, but the reality is that we are just switching out the term Monopoly for an Oligarchy. Is an oligarchy any different than a monopoly in the sense that it’s just a smaller group carving out the biggest slices for themselves, eliminating competition by means of out maneuvering or outspending their opponent in an effort to influence policy such as this? Consider that the biggest lobby against the cannabis Industry is the pharmaceutical industry, yet they’re simultaneously studying cannabis for the purpose of synthesizing its many chemical compounds to create their high margin drugs.

Currently, their high margin bread and butter are the opioids for pain management such as OxyContin, Percocet and their generic versions of each. The drug companies are experts at isolating molecules from nature to create drugs that cost pennies to manufactures. In a zero sum game, cannabis is a direct threat to pharma companies, by snatching billions in profit and simultaneously causing billions in losses. Anti-cannabis lobbies would also be at risk as the pharmaceutical giants that feed them down on K Street would lose out on easy paydays. These anti-Marijuana lobbyists provide a micro look at the systemic problems within American politics illustrating how/why elected officials in Congress consistently vote against the interests of their collective constituency and bring forth carefully crafted bills or amendments like this one.

On the DEA’s policy statement and legal considerations section, under, legal applicable considerations it states.

“Second, as with any application submitted pursuant to section 823(a), in determining whether the proposed registrationwould be consistent with the public interest, among the factorsto be considered are whether the applicant has previous experience handling controlled substances in a lawful manner and whether the applicant has engaged in illegal activity involving controlled substances. In this context, illegal activity includes any activity in violation of the CSA (regardless of whether such activity is permissible under State law) as well as activity in violation of State or local law. While past illegal conduct involving controlled substances does not automatically disqualify an applicant, it may weigh heavily against granting the registration.”

Translation, grow marijuana even in a state where it’s legal and you are going to have a hard time becoming a manufacturer or researcher for the DEA’s new policy, thus excluding tier one cultivators in practice and likely creating a perpetual home for cannabis on the scheduling list. Prohibition’s end could very well be right around the corner, but the fear is in the form of legal medical marijuana at a Walgreens near you. I asked the DEA’s Russ Baer directly if the inserted language above in bold would be a non-starter for current cultivators wanting to become manufacturers as they are in clear Violation of CSA? In a written statement to Marijuana Stocks the DEA’s official response was:

“DEA is serious about facilitating marijuana research and that there is a lawful pathway for doing so. This DEA decision will facilitate increased research involving marijuana, within the framework of the law and U.S. treaty obligations, to enhance the drug’s supply available to researchers. The goal of this historic and monumental policy shift is to increase the amount and variety of marijuana available to researchers and make it easier for researchers to obtain marijuana as compared to current system under which marijuana must be obtained from NIDA. Growers must become registered with DEA, following the submission of an application, which DEA will evaluate in accordance with the CSA. Registered growers will need to comply with all CSA regulatory requirements, such as quotas, record keeping, order forms, and maintenance of control against diversion. Marijuana produced under this proposal may only be supplied to DEA-registered manufacturers and researchers, and only for purposes authorized by the CSA.

All potential new drugs, including drug products made from marijuana, are subject to the rigors of the drug approval process mandated by the Federal Food, Drug and Cosmetic Act (FDCA). This drug approval process requires that before a new drug is allowed to enter the U.S. market, it must be demonstrated through sound clinical trials to be both safe and effective for its intended uses,” stated Russ Baer of the Drug Enforcement Agency.

When asked if the inserted language also creates an unfair advantage for Pharma companies the response from the Drug Enforcement Administration circled back to the CSA (Controlled Substance Act) stating that the “DEA has adopted a new policy, consistent with the CSA and U.S. treaty obligations, under which additional entities may become registered with DEA to grow and distribute marijuana for research purposes. DEA will evaluate each application it receives to determine whether adding such applicant to the list of registered growers is necessary to provide an adequate and uninterrupted supply of marijuana to researchers in the U.S. In addition, applicants must demonstrate their ability to safely secure the drugs to prevent diversion, while abiding by the approved research protocol.”

The Controlled Substance Act

Everything points back to the Controlled Substance Act, a bill that was introduced into the Congress by Harley Staggers and took less than 6 weeks to get passed by the Senate and signed into law by President Richard M. Nixon. The signing of this document not only created the “War on Drugs,” but put an enforcement agency (DEA) in charge of Cannabis scheduling, circumventing the FDA in a move that creates an inter-agency firewall of sorts. The DEA’s position on why the FDA, who already regulates pharmaceutical drugs, isn’t in charge of marijuana rescheduling was point blank, “The Controlled Substances Act provides a mechanism for substances to be controlled (added to or transferred between schedules) or decontrolled (removed from control). The CSA provides roles for DEA and the FDA. Proceedings to add, delete, or change the schedule of a drug or other substance may be initiated by DEA, HHS, or by petition from any interested party. Once initiated, the process involves a deliberate and collaborative interagency exchange.”


In Laymen’s terms CSA effectively says “DEA you’re in charge of this, FDA you’re in charge of that.” Unfortunately, Marijuana will never be completely removed from the scheduling list unless there is a major political overhaul in every branch of government, if and only if elected officials stop letting lobbies pour honey in their ears and money into campaigns. The reality from my perspective is that the DEA is a scapegoat, the perfect Boogey Man, simply because their job is to follow orders. They are soldiers in a sense, adhering to the guidelines of the Controlled Substance Act (CSA), a legal document crafted by a congress, molded in the image of benefactors, used to fuel a fake war and create cottage industries.

The DEA knows marijuana is safer than Oxy and that’s not speculation that’s a direct quote. They don’t want to go after the mother transporting medication to her sick child because they’re suffering from seizures. They want the dangerous individuals like El Chapo or the pill mills slinging Oxy off the streets. They have no interest in going after all cultivators following state law to the letter. Are there exceptions, of course! Does it make these comments directly from them any less true? No.
DEA’s direct position on which drug is more dangerous from a consumption standpoint as it relates to Cannabis vs OxyContin? “There were more than 47,000 drug overdose deaths in 2014, or approximately 129 per day, more than half (61 percent) of which involved either a prescription opioid or heroin. Marijuana meets the statuary criteria of a Scheduled I controlled substance, and has been determined to have a high abuse potential with no currently accepted medical use. Schedule I includes some substances that are exceptionally dangerous (including heroin and LSD) and some that are less dangerous (including marijuana, which is less dangerous than some substances in other schedules).” When asked point blank, what’s more dangerous Oxy or Marijuana DEA says “Oxy.”

Robert Capecchi, Director of Federal Lobbying at the Marijuana Policy views medical marijuana legalization as a means to an opioid end as well as fiscal no brainer with far reaching benefits.

“Ending marijuana prohibition will allow licensed businesses to cultivate, distribute, and sell marijuana to adults. Unlike the criminal market, a legal and regulated market means products are pure, tested and labeled, sales are taxed, and business disputes are resolved in the courts, not with violence. Additionally, there is promising evidence to suggest that legal access to medical marijuana reduces the rates of opioid overdoses and the reliance on prescription pain killers.”

Foregone Conclusion?

Prohibition’s end could very well be right around the corner, but would we want it in the form of legal medical marijuana at a Walgreens near you? August 11th’s ruling was either one of many dominos in the quest for the monopolization of cannabis or just a pessimistic idea based off of history repeating itself. Regardless of which reality we are presently in, it doesn’t hurt to try and connect the dots, but if I can leave you with one last thing it’s the number 6630507. In case you’re wondering that’s the United States patent # they filed for cannabis in 2003 citing “multiple therapeutic uses.” I can only postulate why they did that….


Jason Spatafora

Drug War

11 10903

The biotech sector may be one of the biggest beneficiaries of the legal cannabis movement.

In previous articles, we have been quite vocal about our bullish stance on the cannabis biotech sector. In the current US markets, we believe the greatest opportunity lies in biotech and the pharmaceutical production of cannabinoid and cannabis related drug treatments. And recent political shifts may have just created a perfect storm for cannabis biotech investors. Right now could be your greatest opportunity to consider adding cannabis biotech to your portfolio. And we aren’t the only ones who think so.

Todd Hagopian, manager of a biotech fund at Marketocracy, believes the biotech sector will benefit most from a Donald Trump Presidency. Todd is one of the most successful biotech investors in the market today. His returns have averaged 26.03% since starting his fund in 2011, which compares nicely to the S&P 500’s 11.58% return over the same period. Over the last five and three year periods, Todd Hagopian did better than the top U.S. Equity fund managers.

But why are we so bullish on cannabis biotech?

For over a year, analysts have been anticipating and factoring in a Hillary Clinton victory that sent the ishares NASDAQ Biotechnology ETF (IBB) plummeting 23% from 9/21/15 through Election Day this November. Why? Clinton was very vocal about her desire to slash what she believed to be excessive profits in the biotech industry. This would force drug companies to lower prices that would tighten margins and decrease net profit. If Clinton won the election, there were concerns that she would flip the Senate and/or House of Representatives to Democratic control. This would have allowed her to take action on the pricing practices of the biotech sector.

But with the White House and Congress now in Republican control, the biotech sector is set up for an extraordinary comeback. In fact, it has already begun. The IBB is up about 10% since Election Day. With Trump taking the White House, biotech investors could be in for one heck of a ride as this could be just the beginning of a move that could see the biotech sector double.

In an interview with Ken Kam of Forbes, Todd Hagopian said, “After underperforming the S&P 500 by over 30% in the past 14 months, there is plenty of room for this sector to run. In fact, the S&P 500 Biotechs are trading at a Forward P/E of just 22.4% vs. Consumer Staples who are trading at a Forward P/E of 17.2%.  This is pretty remarkable, considering that the same group of Biotech companies have a short term earnings growth rate of 17.3%, versus the Consumer Staple companies who are projected to grow at just 8.0%. Basically, this data would seem to suggest that either there is a huge bubble in Consumer Staples stocks, or the Biotechnology market is about to double.”

This is the perfect storm for cannabis biotech investors. Not only is the overall biotech industry expected to experience a massive bull run, but cannabis legalization is quickly spreading across the US. The November Election Day was an enormous victory for the cannabis industry. There are now 8 states that allow the recreational use of marijuana and another 21 that allow its medical use. We could be looking at a golden opportunity for cannabis biotech investors.

In his interview with Forbes, Hagopian went on to name a few other catalysts that biotech investors seem to have in their favor:

  1. The Obamacare fight needs to stay away from pricing. The odds of a Republican House and Senate trying to pass a law regulating drug prices, and have it signed by a Republican President seems slim to none.
  2. The Supreme Court needs to stay conservative. Donald Trump has already promised to nominate conservative judges to the court. The Supreme Court will likely stay 5-4, or even 6-3, in favor of conservative views.
  3. M&A activity needs to restart. The low valuations seen in the biotech sector after the Clinton selloff mentioned earlier in this article has sparked a ton of M&A rumors in the biotech sector. The Clinton biotech scare not only provided great opportunity for individual investors but also for large biotech titans to swallow up smaller companies with promising intellectual property and clinical data from early drug trials. We have already seen recent M&A activity in the cannabis sector with Canopy Growth Corp., Canada’s largest marijuana company, agreeing to buy competitor Mettrum Health Corp. for $8.42 a share.

The current environments of the overall biotech sector and marijuana industry have created an exciting time for cannabis biotech investors. Several catalysts are aligning for what could be a booming 2017 for the entire space. In addition, many companies are expected to announce FDA clinical and pre-clinical trial data soon. Favorable results will be a catalyst to send individual stocks and the overall cannabis biotech sector considerably higher.

If you haven’t done so already, it’s time to consider adding cannabis biotech to your portfolio, Now!

1 2234

DENVER, Nov. 2, 2016 /PRNewswire/ — MassRoots, Inc. (MSRT), one of the leading technology platforms for the cannabis industry, is pleased to announce that it has released product and strain reviews within its iOS and Android applications. Through community-driven reviews, MassRoots aims to connect consumers with the best products to treat their ailments.

“There are currently tens of thousands of strains and products in the regulated cannabis industry, making it difficult for consumers to find the best ones to treat their ailments, such as back-pain or nausea,” stated MassRoots CEO Isaac Dietrich. “Through community-driven reviews, we’re enabling our passionate user base to easily provide this information and then present it in a meaningful way for everyday people to make cannabis purchasing decisions.”

MassRoots is accessible in every state with a medicinal or recreational cannabis law. On November 8, 2016, nine states will be voting on initiatives to regulate the production and sale of cannabis, potentially expanding the regulated cannabis market from around $7 billion in 2016 to more than $23 billion by 2020 according to ArcView Market Research. MassRoots expects the continued addition of new features to its platform combined with expansion of the regulated cannabis market could significantly accelerate its user growth and potential revenues.

About MassRoots
MassRoots is one of the largest technology platforms for the regulated cannabis industry. It is proud to be affiliated with the leading businesses and organizations in the cannabis industry, including the ArcView Group and National Cannabis Industry Association. MassRoots has been covered by The Hill, Denver Post, Fortune, Forbes, and CNBC. For more information, please visit MassRoots.com/Investors.

Forward-looking Statements
Certain matters discussed in this announcement contain statements, estimates and projections about the growth of MassRoots’ business, partnerships, new features, and related business strategy. Such statements, estimates and projections may constitute forward-looking statements within the meaning of the federal securities laws. Factors or events that could cause our actual results to differ may emerge from time to time. MassRoots undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The recipient of this information is cautioned not to place undue reliance on forward-looking statements.

    0 4037

    In less than two weeks, the cannabis industry will take a significant step forward as nine states vote on legal cannabis ballot initiatives. Of those nine states, none are more significant than California which is poised to expand the legal recreational marijuana market to almost a quarter of the American population.

    We expect to see Proposition 64 which would legalize recreational cannabis in California pass as polls continue to show strong support. The passage of this ballot initiative would not only have a significant impact on the landscape of the legal cannabis industry but would also serve as a major catalyst to California-based cannabis businesses.

    The Fastest Growing Industry in the World

    In 2015, California accounted for $2.7 billion in sales of medical cannabis product. If Proposition 64 passes, the medical and recreational cannabis market should be a $6.5 billion industry by 2020. The Guardian expects to see $1.6 billion in sales of recreational cannabis products in the first year of legalization.

    From an investor standpoint, there are several ways to capitalize on this opportunity but the best and easiest avenue is through investing in publicly traded companies. Although the cannabis sector continues to fly high, we believe that several high-quality publicly traded cannabis companies are still flying under the radar.

    One such company is Finore Mining Inc. (FIN: CSE) (FNREF: OTC), which is levered to the California cannabis industry following its acquisition of KushTown USA LLC, a California based cannabis infused products company that is a leader in the cannabis beverage industry.

    Levered to the California Cannabis Industry

    Finore entered into an agreement for the acquisition of KushTown on late Thursday and the market responded very favorably, sending FIN and FNREF 23% and 103% higher.

    KushTown specializes in medicated water, soda, hot sauce, and barbecue sauce products infused with cannabis. The company offers 20 different varieties of medicated sodas on its website and its mission is to become an integrated cannabis brand across all of North America as deregulation measures continue to open new markets.

    KushTown has a proven track record of success and has been selling cannabis infused products since 2008. The company’s products are sold in more than 500 dispensaries across California. The company is focused on penetrating new markets within California as demand for cannabis infused products continues to grow.

    KushTown was founded by Peter Moret in 1999 after his mother was diagnosed with breast cancer. Peter successfully created a medical cannabis tincture that he gave to his mother in tea and it improved her appetite, made her more active, and made it easier for her to deal with cancer related pain. In the following year Peter’s mother won her battle against cancer. The decision was then made to manufacture and distribute the tincture called KushTown.

    Product Expansion Should Significantly Increase Market Penetration

    Over the next two years, KushTown plans to expand its product line to include mints, sublingual strips, fudge bars, capsules, chocolate truffles, and oil cartridges for vaporizer pens.

    KushTown plans to become a vertically integrated cannabis company across the United States and it is focused on controlling the entire cultivation process, from seed-to-sale, which will provide increased transparency and visibility into the product quality and integrity.

    Not only does vertical integration improve transparency but it will also have a significant impact on margins and will improve the company’s bottom line through economies of scale.

    Focused on Growth

    KushTown plans to expand through strategic partnerships and is actively seeking partners to license its brand in states where medical and recreational cannabis is legal.

    KushTown is also focused on expanding through acquisitions as well as license applications in states with a legal recreational market and states that are preparing to legalize recreational cannabis. The company plans to roll out a national branding and marketing strategy across all of its product lines while expanding into new state markets.

    Aside from the 500+ dispensaries selling KushTown’s products, several California-based delivery services distribute its products to clients across the state. The company is currently building an e-commerce platform that will lead to increased revenue opportunities as it will allow for direct sales to distributors and consumers.

    Attractive Opportunity Due to Upcoming Catalysts and Recent Acquisition

    Although the shares are trading near its 52-week high, we are favorable on Finore due to the following reasons: 1) Through KushTown, the company is levered to the California cannabis industry which is poised to see massive growth on a year-over-year basis, 2) The company has a proven track record of sales and it has an extensive product line that is in high demand, 3) Cannabis infused products represent a huge part of the legal cannabis industry and it continues to see strong growth, 4) The company is led by a management team with a proven track record of success, and 5) It is levered to the results of the election and market sentiment which should cause its shares to move significantly higher if recreational cannabis is legalized in California.


    Authored By: Michael Berger

    1 2291

    CHEYENNE, Wyo., Oct. 31, 2016 /PRNewswire/ — FBEC Worldwide, Inc. (FBEC), a lifestyle brand company with a focus on Healthy Hemp Energy™ & CBD infused consumer products, is pleased to announce that it has launched a fall clearance sale for its existing stock of WolfShot™ Healthy Hemp Energy™ Shot. FBEC has recently announced an initial order for 40,000 more WolfShots™ to meet an increase in product demand, this Fall Clearance Sale will allow the company to clear out existing inventory and make room for new inventory.

    To take advantage of FBEC’s Fall Clearance Sale Visit http://wolfshot.healthyhempenergy.com/. Select your products and at checkout select “Have a coupon? Click here to enter your code” and enter coupon code “FALL2016” and receive a 30% discount & 2-day expedited shipping for the price of ground.

    CEO Jeff Greene stated “As we prepare to move forward into the 2016 Holiday season and even into the new year we want to do so as efficiently as possible. We have a lot of new inventory coming in. We want to make sure that we are pushing our existing inventory to make room for the new.”

    About FBEC Worldwide, Inc.

    FBEC Worldwide, Inc. is a lifestyle Brand Company with a focus on Healthy Hemp Energy™ & CBD infused consumer products, both domestic and abroad. We are committed to increasing our market size and scope through the optics of creative marketing and most importantly customer satisfaction. Our growth strategies focus on a number of major initiatives, including unique branding opportunities that will be targeted at key demographic groups and to develop strong community and distributor relationships.

    FBEC Worldwide is currently developing and building Healthy Hemp™ & CBD infused consumer products, focused on strong rates of growth within key fundamental consumer groups. Our company is dedicated to becoming the lead developer of name brand hemp & CBD infused consumer products.

    Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The Company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

    Investor Relations Contact:

    Joe Sirianni
    MIDAM Ventures LLC
    (305) 707-7018

    1 4973

    Arcturus Announces Engagement of Financial Advisor for Vertical Farm Project

    VANCOUVER, British Columbia, September 29, 2016 /PRNewswire/ —

    Arcturus Growthstar Technologies Inc. (the “Company” or “Arcturus”) (CSE:AGS) (OTC Pink: AGSTF) is pleased to announce that it has engaged the services of CBO Financial, Inc. as its financial advisor with respect to New Market Tax Credits (NMTC) for a vertical farm project. The NMTC program is a $65 billion federal program designed to incentivize private investment in low-income communities. NMTCs are provided to financial institutions in exchange for equity investments that eligible businesses can use to subsidize project development costs. CBO Financial helps driven organizations, such as Arcturus, to finance facilities that will provide goods and services that benefit populations in need and revitalize communities. Arcturus’ partnership with CBO Financial is both shareholder and capital structure friendly in the sense that the draw of capital is non-dilutive in nature.

    “We are very pleased to have engaged CBO Financial,” says Mr. William Gildea, Arcturus Growthstar Technologies, Inc.’s CEO and Chairman. “CBO Financial is an invaluable resource. We plan to work with CBO Financial to navigate the NMTC qualifying and application process as a means of bringing additional capital to our vertical farming project.”

    Mr. Craig Stanley, CEO and Founder of CBO Financial states, “[t]he CBO Financial team is excited to be selected by Arcturus to assist with securing New Markets Tax Credits for the vertical farm project. CBO has been involved in this program since its inception in 2004 and has received direct awards in six out of thirteen annual rounds totaling $150 million, one of a small number of groups in the U.S. to have received six or more awards. In addition CBO has secured over $500 million in NMTCs for clients. The NMTC program provides 20% to 25% of a project cost in very flexible financing for projects located in low-income communities. We hope this is the first of many projects with Arcturus. For more information see http://www.cbofinancial.com .”

    On behalf of the Board,

    Arcturus Growthstar Technologies Inc.

    William Gildea, CEO & Chairman

    About Arcturus

    The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants. Arcturus provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generate yields up to 10 times greater per square foot of land. The contained system provides many other benefits including seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability.

    The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com which caters to B2B customers is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com which caters to both large and small agriculture green houses and controlled cultivation centers.

    Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

    This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

    Suite 1518, 1030 West Georgia Street
    Vancouver, British Columbia
    V6E 2Y3

    William Gildea,

    1 2660

    CHEYENNE, Wyo., Sept. 26, 2016 /PRNewswire/ — FBEC Worldwide, Inc. (FBEC) a lifestyle brand company with a focus on Healthy Hemp™ & CBD infused consumer products, is pleased to announce that Amazon.com, Inc. (AMZN) has received FBEC’s WolfShot™ brand of Healthy Hemp™ Energy Shots & is now available for sale on Amazon.com. Wolfshot™ can be purchased here https://www.amazon.com/gp/product/B01IC71UGA.

    This announcement comes after the company announced on September 14, 2016 that it had received a follow up purchase order after a successful test run of WolfShot™ via the Amazon Vendor Express Program. Amazon’s Vendor Express Program allows companies like FBEC Worldwide, Inc. to sell their products directly to Amazon.com, Inc. (AMZN). Amazon takes care of the shipping, promoting & customer service.

    CEO Jeff Greene stated, “Current & potential customers can once again visit Amazon.com & purchase FBEC’s WolfShot™ brand of Healthy Hemp™ Energy Shots. After our previous successful test run with Amazon Vendor Express we look forward to a continued positive reception of our products.”

    About FBEC Worldwide, Inc.

    FBEC Worldwide, Inc. is a lifestyle Brand Company with a focus on Healthy Hemp™ & CBD infused consumer products, both domestic and abroad. We are committed to increasing our market size and scope through the optics of creative marketing and most importantly customer satisfaction. Our growth strategies focus on a number of major initiatives, including unique branding opportunities that will be targeted at key demographic groups and to develop strong community and distributor relationships.

    FBEC Worldwide is currently developing and building Healthy Hemp™ & CBD infused consumer products, focused on strong rates of growth within key fundamental consumer groups. Our company is dedicated to becoming the lead developer of name brand hemp & CBD infused consumer products.

    Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The Company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

    Investor Relations Contact:

    Joe Sirianni
    MIDAM Ventures LLC
    (305) 707-7018

    An affiliate of MAPH Enterprises, LLC MarijuanaStocks.com | WolfofWeedStreet.com was paid an advertising fee of $60,000 cash & 60 Million Restricted Common shares by FBEC Worldwide Inc. (FBEC) for visual sponsorship of MarijuanaStocks.com | WolfofWeedStreet.com and for visual placement FBEC Worldwide Inc. (FBEC) within written materials. FOR A DURATION OF 5 YEARS BEGINNING JUNE 2015 ending JUNE 2020


    1 2882

    American Green Consolidates Office to Phoenix Cultivation Site

    TEMPE, AZ–(Marketwired – Sep 20, 2016) – American Green, Inc. ( OTC PINK : ERBB ) consolidated its primary office with its Phoenix cultivation site to achieve the greatest operational efficiency for both its current and future undertakings. Besides the future grow facility revenue expected at the site, day-to-day engagement with the process has already produced up to three additional locations for duplication. By reducing to dedicated staff who are willing to work building real company value and a willingness to be on location, the company is already experiencing positive growth. The location of the facility will be made public once the signage is up and site-insurance riders are in place. In spite of the current trend to hide such locations, American Green is confident that its security measures will enable the company to be as transparent in its progress as it can be. The goal is to allow shareholder tours throughout the facility beginning sometime in October.

    “After a month of analysis, the Board of Directors and consulting staff have determined that the past plan needed a serious overhaul favoring simplicity and speed,” says David Gwyther, American Green chairman and acting president. “The move comes at a time when both the company and market forces require steadfast, focused effort and commitment to a clear plan designed to insure overall corporate health when the inevitable upswing arrives which will likely benefit those cannabis-connected companies left standing. There are some that over-build because they can, and those that can’t quite achieve lift-off. Our numbers show that for who we are and where we are, this is the best possible scenario,” Gwyther concludes.

    Incorporating fundamental, yet quality building methods with state-of-the-art materials, the site will feature consistency in temperature and humidity, a comprehensive plan for security and hygiene, a limited number of strains targeting primary needs for medicinal marijuana, and an adequate space to expand into the higher-margin extraction business. In a forthcoming update coinciding with the issuance of a Certificate of Occupancy (necessary to begin legal cultivation), American Green’s Phoenix grow facility will publish estimated yields and subsequent revenues based on actual spaces that are built and operational. With the November election and the possibility to legalize ‘recreational’ cannabis, the company believes its current estimates are conservative with a primary goal of operating in the “black” within six months of putting the first plants in their grow medium.

    In other news, The American Green Machine is back. Watch for pending news of the Company’s proprietary next-generation automation system. Demand has caught up with the idea for verified vending of restricted products and the company believes it is positioned to meet and expand on the energized market and growing potential for clients throughout America.

    Be sure to visit the company’s website at www.americangreen.com and sign up for the company’s emails alerts to stay current on news.
    Shareholders and interest holders may also stay current with American Green Updates:

    Twitter: @American__Green (two underscores), or
    Facebook: https://www.facebook.com/americangreenusa


    Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company’s Securities and Exchange Commission reports and filings. Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward-looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, should and similar expressions and by the context in which they are used. Such statements are based upon current expectations of the Company and speak only as of the date made. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which they are made.

    About American Green, Corp.

    American Green, Corp., became one of the first publicly traded technology companies in the medical cannabis industry in the world, beginning in 2009, with the introduction of the ZaZZZ machine for automated, age-verifying dispensing of cannabis-based medicines. Now, with over 50,000 individual shareholders, American Green’s mission is to be the cannabis & industrial hemp industry, seed-to sale innovator, leveraging our team of professionals, as well as value-added companies and products – spanning cultivation, manufacturing and extraction, retail, and community outreach. We strive to develop sustainable businesses, while increasing shareholder value, and awareness beyond our industries.

    1 3228

    GW Pharmaceuticals (GWPH) soared in the last hour of trading Wednesday after Reuters reported that the company hired Morgan Stanley (MS) after it received unsolicited interest from other drug makers.
    The news served as a catalyst to a number of cannabis stocks as share prices jumped 5% to 10% across the board. Does Not Come as a Surprise GW is in a league of their own when it comes to the cannabis industry and this news does not come as a surprise to us.

    In an article published in July, we said, “We would recommend targeting companies like GWPH, INSY and ZYNE, as long-term investments. These companies would be very attractive takeout candidates for big pharma businesses that want to enter the legal cannabis industry.”

    In March, GW changed the landscape of the cannabis industry when it reported positive data from its Stage 3 Clinical study on its Epidiolex product for the treatment of Dravet syndrome. GW reported similar results in May but this time it was for the treatment of Lennox-Gastaut syndrome (LGS) with its Epidolex product.
    And we weren’t the only ones on the scent of Biotech Buyouts within the Cannabis Space as Jason Spatafora (@WolfofWeedSt) contributed to a piece in Forbes about Biotech Acquisitions with GWPH, CARA, ZYNE, & INSY all potential targets from ABBV. In the July 26th piece he stated:

    “INSY would be the obvious first choice for ABBV because if they acquired INSY they get Syndros, which AbbV’s patients could switch over to due to the efficiency of the drug. My feeling is Abbv could acquire a few companies in this space such as Cara Therapeutics (CARA), Zynerba (ZYNE), and GW Pharmaceuticals (GWPH). Their purchase of Pharmacyclics for $21 Billion last year shows they aren’t scared to spend money and a move like this (if approved) would have them dominating the space.”

    That article can be read here

    Only Pure-Play Biotech Cannabis Stock Unlike Insys Therapeutics (INSY) and Zynerba Pharmaceuticals (ZYNE), GW actually utilizes the cannabis plant to derive its medicines.
    Insys and Zynerba are focused on developing treatments with synthetic cannabis, which differs from GW’s approach.

    Although ZYNE and INSY take a different approach, both shares rallied off of GW’s news. The shares rallied 8.5% and 5.7%, respectively and we were surprised by some of ripple effects created by this news.
    What Stocks Benefited?

    Terra Tech Corp (TRTC): After trading mildly higher for most of the day, TRTC jumped 10% following the GW news and the shares ended the day up 12.3%.

    India Globalization Capital (IGC): The shares were trading at $0.45 for most of the day and then IGC jumped more than 12% after the GW news was reported. IGC ended the day up more than 20% and volume was 5x times higher than its monthly average. IGC is trading at $0.52 and the shares are now trading above its 20, 50, and 150 day moving average.

    Cara Therapeutics (CARA): The shares were trading in the $5.70-$5.80 range for most of the day and then shares jumped above the $6 level after the news was reported. CARA rallied more than 6.1% yesterday and the shares are trading at $6.02 after this move.

    By Michael Berger of Technical420.com

    Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

    We are your #1 source for all things Marijuana Stocks, Subscribe Below!

    Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
    Ad Placements